Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the ...

As with all products, we will keep its safety under close review. The Medicines and Healthcare products Regulatory Agency ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

In 2023, the U.S. Food and Drug Administration approved a treatment for Friedreich’s Ataxia, although it is not a cure. The agency based its decision, in part, on studies done by the Ataxia ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application ...